< Ophthalmic Council 2008

Optos

Go to www.optos.com

Optos is a GOLD level sponsor of the American Optometric Association.

Optos

sponsors the following AOA programs:

As of February 2008

Optometry's Meeting™

Breakfast Seminar
Specialty OD Education Course

Other Programs

AOA Wellness Public Relations Initiative

Optos plc is a leading and rapidly growing medical technology company for the design, development, manufacturing and marketing of devices that image the retina.

Optos’ platform technology is the Panoramic200 Scanning Laser Ophthalmoscope device—known as the P200. In a quarter of a second, the P200 device produces a high-resolution image of up to 200 degrees or approximately 82 percent of the retina in a single capture. The image—branded the optomap® Retinal Exam—provides eye care practitioners with clinically useful information that facilitates the early detection of disorders and diseases evidenced in the retina, such as glaucoma, diabetic retinopathy and age-related macular degeneration.

The Optos P200 device is placed in a practice’s pretest area and networked into the doctors’ examination lanes. The patient’s optomap image is then captured in the pretest area and reviewed with them interactively in the lane with the doctor. This adds tremendous value to doctor-patient communication and brings the eye exam to life. The optomap Retinal Exam contributes greatly to enhanced clinical capabilities and adds tremendously to the patient’s eye care experience.

Additionally, Optos’ offers optomap® plus Medical Retinal Exam, a procedure for medically necessary disease management and follow-up. The optomap plus allows practitioners to document that a specific capture and review process has been followed and provides advanced annotation tools, such as measurement and ISNT Ratio measurement tools, for objective assessment and identification. This evidence can then be used to support reimbursement claims as required.

Optos recently introduced the latest version of its proprietary operating software—V2® Vantage. It is now available to all new partners and is currently being rolled out to the Optos customer base. The new software offers many new, innovative clinical advancements that will be beneficial to both the practitioner and patient. The new features include: 3D Wrap™ Patient Orientation Tool, ResMax™ High Resolution Enhancement for Central Pole, Practice Performance Statistics, Targeted Ophthalmoscopy Mode, and more.

“The introduction of V2 Vantage delivers on a key promise within our customer partnership agreements to keep our customers on the leading edge of retinal imaging technology,” said Thomas W. Butts, chief executive officer, Optos plc. “We expect V2 Vantage to be particularly helpful to our customers in secondary care who are performing the optomap plus Medical Retinal Exam.”

To promote the successful integration of the optomap Retinal exam into practices, Optos provides its customers with a wealth of technical, educational and marketing resources, including on-site staff and physician training, best practice protocols, patient education materials and marketing outreach programs, as well as continued maintenance and customer support.

As of Sept. 30, 2006, Optos had 232 employees serving more than 2,500 customers in the company’s existing markets, currently the United States, Canada, the United Kingdom and Germany. Optos plc is headquartered in Dunfermline, Scotland, and was admitted to the Main Market of the London Stock Exchange on Feb. 15, 2006, trading under the symbol OPTS. The company’s North American headquarters is based in Marlborough, MA.